Citizens analyst Reni Benjamin initiated coverage of Whitehawk Therapeutics with an Outperform rating and $8 price target. Whitehawk is advancing three antibody-drug conjugates \"against clinically validated targets\" with initial proof of concept data expected in the first half of 2027, the analyst tells investors in a research note. The firm sees the shares as attractive, with 75% downside in a bear case scenario and 150% upside in a bull case scenario. Whitehawk is positioning itself for the next wave of therapeutics going after novel targets which have largely been clinically validated, contends Citizens.
